The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 22, 2019

Filed:

Nov. 27, 2018
Applicants:

Salk Institute for Biological Studies, La Jolla, CA (US);

The University of Sydney, Sydney, AU;

Inventors:

Ronald M. Evans, La Jolla, CA (US);

Michael Downes, San Diego, CA (US);

Annette Atkins, San Diego, CA (US);

Sungsoon Fang, La Jolla, CA (US);

Jae Myoung Suh, San Diego, CA (US);

Thomas J. Baiga, Escondido, CA (US);

Ruth T. Yu, La Jolla, CA (US);

John F. W. Keana, Eugene, OR (US);

Christopher Liddle, Chertswood, AU;

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 231/56 (2006.01); C07C 233/63 (2006.01); C07B 59/00 (2006.01);
U.S. Cl.
CPC ...
C07D 231/56 (2013.01); C07B 59/001 (2013.01); C07B 59/002 (2013.01); C07C 233/63 (2013.01); C07B 2200/05 (2013.01); C07C 2601/14 (2017.05); C07C 2602/42 (2017.05);
Abstract

Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.


Find Patent Forward Citations

Loading…